Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2014 3
2015 2
2016 3
2017 1
2020 2
2021 1
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS, Schieffer KM, Lee K, Cottrell CE, Wang PY, Mardis ER, Cripe TP, Chandler DS. Venkataramany AS, et al. Ann Oncol. 2022 Jun;33(6):578-592. doi: 10.1016/j.annonc.2022.03.011. Epub 2022 Mar 23. Ann Oncol. 2022. PMID: 35339647 Free article. Review.
We observe these phenomena in cancer predisposition syndromes (Lynch syndrome, Li-Fraumeni syndrome, CHEK2) and pediatric leukemia (B-cell acute lymphoblastic leukemia), sarcomas (Ewing sarcoma, rhabdomyosarcoma, osteosarcoma), retinoblastoma, W …
We observe these phenomena in cancer predisposition syndromes (Lynch syndrome, Li-Fraumeni syndrome, CHEK2) and pediatric leukemia (B …
Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.
Roy U, Raghavan SC. Roy U, et al. Int J Cancer. 2021 Sep 15;149(6):1210-1220. doi: 10.1002/ijc.33527. Epub 2021 Mar 31. Int J Cancer. 2021. PMID: 33634864 Free article. Review.
T-cell acute lymphoblastic leukemia (T-ALL) is characterized by the leukemogenic transformation of immature T cells, which accumulate an array of genetic and epigenetic lesions, leading to a sustained proliferation of abnormal T cells. ...Novel oncogen …
T-cell acute lymphoblastic leukemia (T-ALL) is characterized by the leukemogenic transformation of immature T ce …
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.
Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM. Levinson AL, et al. Blood Adv. 2023 Jul 25;7(14):3479-3484. doi: 10.1182/bloodadvances.2021006881. Blood Adv. 2023. PMID: 36897249 Free PMC article.
Glucocorticoids (GCs) are the cornerstone of acute lymphoblastic leukemia (ALL) therapy. Although mutations in NR3C1, which encodes the GC receptor (GR), and other genes involved in GC signaling occur at relapse, additional mechanisms of adaptive GC resistanc …
Glucocorticoids (GCs) are the cornerstone of acute lymphoblastic leukemia (ALL) therapy. Although mutations in NR3C1, w …
KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress.
Issa N, Bjeije H, Wilson ER, Krishnan A, Dunuwille WMB, Parsons TM, Zhang CR, Han W, Young AL, Ren Z, Ge K, Wang ES, Weng AP, Cashen A, Spencer DH, Challen GA. Issa N, et al. Leukemia. 2023 Apr;37(4):728-740. doi: 10.1038/s41375-023-01853-9. Epub 2023 Feb 17. Leukemia. 2023. PMID: 36797416 Free PMC article.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic neoplasm resulting from the malignant transformation of T-cell progenitors. While activating NOTCH1 mutations are the dominant genetic drivers of T-ALL, epigenetic dysfun …
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic neoplasm resulting from the malignant …
Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.
Creasey T, Barretta E, Ryan SL, Butler E, Kirkwood AA, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Morley N, Marks DI, Fielding AK, Moorman AV. Creasey T, et al. Haematologica. 2022 Sep 1;107(9):2051-2063. doi: 10.3324/haematol.2021.279177. Haematologica. 2022. PMID: 34788984 Free PMC article.
Despite being predominantly a childhood disease, the incidence of acute lymphoblastic leukemia (ALL) has a second peak in adults aged 60 years and over. ...IKZF1 deletion was present in 51% (40/78) of samples tested and the IKZF1plus profile was identified in …
Despite being predominantly a childhood disease, the incidence of acute lymphoblastic leukemia (ALL) has a second peak …
Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Mar BG, et al. Nat Commun. 2014 Mar 24;5:3469. doi: 10.1038/ncomms4469. Nat Commun. 2014. PMID: 24662245 Free PMC article.
Relapsed paediatric acute lymphoblastic leukaemia (ALL) has high rates of treatment failure. ...We find significant enrichment of mutations in epigenetic regulators at relapse with recurrent somatic mutations in SETD2, CREBBP, MSH6, KDM6A and MLL2, mut …
Relapsed paediatric acute lymphoblastic leukaemia (ALL) has high rates of treatment failure. ...We find significant enr …
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
Spinella JF, Cassart P, Richer C, Saillour V, Ouimet M, Langlois S, St-Onge P, Sontag T, Healy J, Minden MD, Sinnett D. Spinella JF, et al. Oncotarget. 2016 Oct 4;7(40):65485-65503. doi: 10.18632/oncotarget.11796. Oncotarget. 2016. PMID: 27602765 Free PMC article.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with variable prognosis. ...Using an integrative approach combining genomic and transcriptomic data, we molecularly characterized 30 pediatric T-ALLs and identified com …
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy with variable prognosis. ... …
UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.
Benyoucef A, Palii CG, Wang C, Porter CJ, Chu A, Dai F, Tremblay V, Rakopoulos P, Singh K, Huang S, Pflumio F, Hébert J, Couture JF, Perkins TJ, Ge K, Dilworth FJ, Brand M. Benyoucef A, et al. Genes Dev. 2016 Mar 1;30(5):508-21. doi: 10.1101/gad.276790.115. Genes Dev. 2016. PMID: 26944678 Free PMC article.
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous group of hematological tumors composed of distinct subtypes that vary in their genetic abnormalities, gene expression signatures, and prognoses. ...Furthermore, we demonstrate that UTX, pre …
T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous group of hematological tumors composed of distinc …
Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.
Xiao H, Wang LM, Luo Y, Lai X, Li C, Shi J, Tan Y, Fu S, Wang Y, Zhu N, He J, Zheng W, Yu X, Cai Z, Huang H. Xiao H, et al. Oncotarget. 2016 Jan 19;7(3):2696-708. doi: 10.18632/oncotarget.6259. Oncotarget. 2016. PMID: 26527318 Free PMC article.
Although steady improvements to chemotherapeutic treatments has helped cure 80% of childhood acute lymphoblastic leukemia (ALL) cases, chemotherapy has proven to be less effective in treating the majority of adult patients, leaving allogeneic hematopoietic st …
Although steady improvements to chemotherapeutic treatments has helped cure 80% of childhood acute lymphoblastic leukemia …
18 results